Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5937
    +0.0003 (+0.05%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • OIL

    83.45
    +0.09 (+0.11%)
     
  • GOLD

    2,335.90
    -6.20 (-0.26%)
     

Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver

Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver

In June, Novo Nordisk (NVO) presented the results of its Phase 3a PIONEER 1 trial. This trial demonstrated that oral semaglutide significantly decreased the blood sugar levels in individuals with type 2 diabetes compared to placebo therapy.